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Abstract Formoterol and salmeterol are both long-acting bronchodilators that are effective in the treatment of asth- 
ma. However, some differences exist in their pharmacology that are reflected in their clinical profiles. Formoterol has a 
rapid onset of action, whereas salmeterol causes bronchodilation in a somewhat slower mannen However, both of these 
drugs are long-acting. After single doses clear effects are maintained for 12 h after inhalation, and with high doses effects 
are observed even at 24 h. Differences between the maximal effects of both drugs are also a consequence of their phar- 
macological properties.Thus, formoterol has higher intrinsic activity than salmeterol, which means that it is a full agonist, 
whereas salmeterol is a partial agonist on the/82-recepton Physicochemical properties of the drugs may explain the differ- 
ences in onset and duration of action. Adequate water solubility and moderate lipophilicity of formoterol ensures rapid 
diffusion to the j~2-receptor on the smooth muscle and rapid bronchodilating activity. Salmeterol, on the other hand, may 
diffuse more slowly tothe/82-receptor because of its high lipophilicity, explaining the slower onset of action. Unlike salbu- 
tamol, which is hydrophilic and has a rapid onset and short duration of action, both formoterol and salmeterol possess 
adequate lipophilic properties to remain in the airway tissues as a depot in close vicinity to the/82-receptor, explaining 
their long duration of effect.The long duration ofsalmeterol has also been suggested to depend on an anchored binding 
within the/82-receptor (I). The pharmacological evidence for a rapid onset of action offormoterol, but long duration of 
effect, is supported by several clinical studies. The fast onset of bronchodilation and high intrinsic activity offormoterol 
therefore suggest that it can be used for relief treatment in patients with asthma if they are concomitantly treated with 
inhaled glucocorticoids. 
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INTRODUCTION 
Formoterol and salmeterol are both long-acting/82-adre- 
noceptor agonists (/82-agonists), but their pharmacologi- 
cal and clinical profiles differ in several ways (Table I) (2). 
In particular, formoterol has a rapid onset of action 
(within minutes), whereas salmeterol causes bronchodi- 
lation more slowly. Salbutamol and terbutaline are/82- 
agonists with rapid onset, but a much shorter duration 
of action than both salmeterol and formoterol. Chemical 
differences, affecting the tissue diffusion rates and how 
they interact with the/82-receptor, may explain these 
variations in properties. 
Following inhalation, all asthma drugs are deposited 
on the mucosal lining fluid. After dissolving in this liquid 
layer, they diffuse through the different tissue compo- 
nents deeper into the bronchial wall. The most impor- 
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tant target of /82-agonists are /82-adrenoceptors in 
smooth muscle. Binding to the receptor initiates a cas- 
cade of intracellular biochemical events that ultimately 
cause bronchodilation (Fig. I). Briefly, coupling of the t82- 
adrenoceptor, through the Gs protein ~ subunit (Gscc), to 
adenylate cyclase results in an increase in intracellular 
cyclic AMP (cAMP) which leads to protein kinase A being 
activated. Activated protein kinase A inhibits phosphor- 
ylation of key muscle proteins involved in the control of 
smooth muscle tone; cAMP also results in inhibition of 
calcium ion release from intracellular stores. Together, 
these events lead to a general relaxatory effect of the air- 
way smooth muscle; cAMP-independent mechanisms 
may also be involved in the relaxant response and these 
may involve direct interaction of Gs~ with potassium 
channels that are present in the smooth muscle cell 
membrane (3). 
The degree of the bronchodilatory response of a/82- 
agonist is related to the concentration of drug in the vici- 
nity of the smooth muscle cells and the degree of activa- 
tion of the receptor by the /82-agonist. The onset of 
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Figure I. Biochemical mechanisms involved in smooth muscle 
relaxation following fl2-adrenoceptor activation, cAMP: cyclic 
adenosine monophosphate; PKA: protein kinase A; ATP: adeno- 
sine triphosphate. 
bronchodilation and the duration of effect of an inhaled 
drug are influenced by the time it takes for effective con- 
centrations of the drug to be reached and maintained at 
the receptor site. 
RECEPTOR INTERACTION 
Formoterol, salmeterol, salbutamol and terbutaline have 
clear differences in their chemical structure, conse- 
quently their interaction with fl2-receptors may differ 
to some extent. Subtle variations in the electrochemical 
shape of their head groups (Fig. 2) affect the strength of 
the interaction between the agonist and receptor and, 
therefore, influence the degree of signal transduction. 
Formoterol has additional methoxy groups in the side 
chain, which enables the drug to bind to the receptor 
with high affinity and leads to efficient signal transduc- 
tion (2,4). By contrast, salmeterol does not change the 
shape of the receptor to such a degree that full signal 
transduction is achieved. Salmeterol is, therefore, a par- 
tial agonist in relation to formoterol, which explains the 
lesser degree of maximal dilatation by salmeterol of se- 
verely contracted tracheobronchial smooth muscle (5,6) 
(Fig. 3). 
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Figure 2. Chemical structures offormoterol, salmeterol and salbutamol. 
PHARP1ACOLOGYOF FORNOTEROL $9 
ONSET OF ACT ION AND DURATION 
OF EFFECT 
The mechanism for the long duration of action of inhaled 
salmeterol and formoterol has been debated. Some data 
from cell molecular experiments, showed that some very 
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Figure 3. Cumulative dose response curves of formoterol, 
salmeterol and salbutamol in severely constricted (carbachol 
3 l~kl) isolated guinea pig trachea. As can be seen in the figure, 
focmoterol causes a greater bronchodilation than salmeterol (5). 
specific mutations of the fl2-receptor caused loss of the 
long duration of action of salmeterol, but not formoter- 
ol, and it was, therefore, suggested that anchored bind- 
ing of salmeterol within the/~2-receptor was responsible 
for its long duration of action (I).This explanation may be 
valid for salmeterol, but anchored binding does not ex- 
plain the long-lasting effects of formoterol. It was there- 
fore suggested by Anderson (7) that the lipophilicity of 
formoterol and salmeterol may be responsible for their 
long duration of action. Both formoterol and salmeterol 
have sufficient lipophilicity to enter and be stored in any 
cell membranes, which in the airways would allow these 
drugs to be accessible to fl2-receptors on the bronchial 
smooth muscle for a prolonged period of time (Fig. 4). 
fl2-agonists with greater water solubility, such as salbuta- 
mol and terbutaline, diffuse more readily through the tis- 
sue, but are also washed away more rapidly. 
As well as explaining differences in the duration of ac- 
tion of salmeterol and formoterol, lipophilic characteris- 
tics may also explain differences in their onset of action. 
Although both salmeterol and formoterol partition into 
lipid regions of bronchial tissues and cell membranes, the 
intermediate lipophilicity of formoterol means that a far 
higher proportion of formoterol is retained in the extra- 
cellular space.The result is a rapid diffusion of formoterol 
to/~2-receptors and a fast onset of effect. Salmeterol 
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Figure 4. Membrane and receptor interaction ofsalbutamol, salmeterol and formoterol: the microdiffusion theor7 
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Comparative bronchodilating effects ofsalmeterol 
and formoterol (8). 
diffuses more slowly through lipid regions and its onset of 
action is delayed. 
CLINICAL PROFILES 
The clinical relevance of differences in the pharmacologi- 
cal profiles of salmeterol and formoterol has been con- 
firmed in a double-blind, crossover, clinical study in 
asthma conducted by Palmqvist et aL (8). Both drugs 
showed a bronchodilating effect lasting more than 12 h, 
but formoterol showed a more rapid onset of action 
(Fig. 5).The rapid onset of action of formoterol is, in fact, 
similar to that of salbutamol (9). This could explain why 
formoterol, and not salmeterol, has been documented as 
an effective reliever medication in asthma (10). 
In vitro data also show that formoterol has a higher 
pharmacological efficacy than salmeterol (5) but until re- 
cently this had not been demonstrated in the clinical si- 
tuation. However, it has now been shown that 
formoterol has a higher efficacy than salmeterol in pro- 
tecting against methacholine provocation in asthma pa- 
tients (11) (Fig. 6). This study supports the view that 
formoterol has dose-dependent effects and that addi- 
tional effects are achieved if the dose of formoterol is in- 
creased. 
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Figure 6. Bronchoprotection offered by salmeterol and for- 
moterol against methachotine provocation (I I). PD20: provoca- 
tive dose producing a 20% fall in FEVI. 
A more rapid onset of systemic side effects with for- 
moterol, in comparison with salmeterol, is expected in 
line with its rapid onset of action and high efficacy. This 
was indeed found in the previous study evaluating airway 
efficacy (11), and has been confirmed in a recent dose-re- 
sponse study in healthy volunteers (12). Both salmeterol 
and formoterol caused an early dose-dependent increase 
in heart rate and glucose concentration and a fall in dia- 
stolic blood pressure and plasma potassium concentra- 
tion. Formoterol also caused an early increase in systolic 
blood pressure. The cardiovascular effects occurred 
more rapidly than the metabolic effects and the re- 
sponse to formoterol was faster, apart from the glycae- 
mic response, than that of salmeterol. However, the 
effects of salmeterol in general were more prolonged. 
These results are in line with the recent report that for- 
moterol has a similar duration of systemic effects to tra- 
ditional short-acting fi2-agonists such as salbutamol (13). 
Both healthy subjects and asthmatic patients were eval- 
uated and the systemic responses were more pro- 
nounced in the healthy subjects than in the asthmatics, 
which is probably the result of induced tolerance to the 
systemic effects during regular formoterol treatment. 
Importantly, the reduction in serum potassium levels, a 
surrogate marker for systemic side effects, was not pro- 
longed with formoterol when compared with an equi- 
effective concentration of salbutamoI.This confirms ear- 
lier data showing that formoterol at higher doses is not 
long acting in terms of serum potassium and electrocar- 
diographic changes compared with terbutaline (14). In 
practice, systemic side effects are seldom a problem with 
formoterol. 
CONCLUSIONS 
Differences in the pharmacological properties of formo- 
terol and salmeterol are reflected to a large extent in 
their clinical profiles. Thus, formoterol has a higher effi- 
cacy than salmeterol in both bronchial smooth muscle 
systems in vitro, as well as in asthmatic patients in vivo. 
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This suggests that  fo rmotero l  wi l l  have addit ive effects in 
the airways when the dose is increased and may, there -  
fore, in the future,  be recommended for  the t reatment  
of  acute asthma (15).This possibi l i ty is fu r ther  suppor ted  
by the rapid onset of act ion of  fo rmotero l  (8,9). Formo-  
tero l  has recently, in a large mul t icentre  study, been 
shown to  be suitable for  as-needed rel ief medicat ion in 
asthmat ic  patients t reated w i th  inhaled g lucocort ico ids  
(io). 
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